Browsing by Author "Ferreira, S"
Now showing 1 - 10 of 15
Results Per Page
Sort Options
- Children with Type 1 Diabetes of Early Age at Onset - Immune and Metabolic PhenotypesPublication . Sales Luis, M; Alcafache, M; Ferreira, S; Fitas, AL; Simões Pereira, J; Caramalho, I; Lopes, L; Limbert, CObjectives We aimed to evaluate children with type 1 diabetes (T1D) with early age at onset (EAO) for clinical, immune and metabolic features in order to identify age-related disease phenotypes. Methods Comparative study of two groups of T1D children: EAO (≤5 years) and later age at onset (LAO; >5 years), regarding the presence of other autoimmune (AI) diseases, diabetes ketoacidosis and immunologic profile at onset and metabolic data 1 year after diagnosis. Statistical analysis was performed with significance set for p < 0.05. Results The study included 137 children (EAO = 52, mean age 3.6 ± 1.5 [mean ± standard deviation (SD)] and LAO = 85, mean age 10.4 ± 2.9). EAO was more associated with concomitant AI diseases (p = 0.032). Despite no differences in disease onset, EAO presented with lower C-peptide levels (p = 0.01) and higher absolute lymphocyte number (p < 0.0001), with an inverse correlation between these two variables (p = 0.028). Additionally, the EAO group had a higher frequency of serum detection of three antibodies (Abs) (p = 0.0008), specifically insulin Abs (p = 0.0001). One year after diagnosis, EAO had higher total daily insulin (TDI) dose (p = 0.008), despite similar hemoglobin A1c (HbA1c). Conclusions Our data show an association of EAO T1D with more AI diseases, higher number of Abs, lower initial insulin reservoir and higher insulin requirements 1 year after diagnosis. In this group, immune imbalance seems more evident and disease progression faster, probably reflecting distinct "immune environment" with different ages at disease onset. Further studies in the field of immunogenetics and immune tolerance are required, to improve patient stratification and find novel targets for therapeutic intervention.
- Disfagia e Disartria. Forma Invulgar de Apresentação da Miastenia GravisPublication . Ferreira, S; Lage, P; Claro, I; Alcântara, J; Nunes, J; Nobre Leitão, CMyasthenia Gravis is an autoimmune disorder that generally presents with ocular symptoms, specially diplopia and ptosis. Dysphagia may be a manifestation of the generalised type of the disease, but rarely is its presenting feature. The authors describe a case of Myasthenia Gravis in an old patient complaining of dysphagia and dysarthria. Because Myasthenia Gravis is a potentially serious but treatable disease, we emphasize the need to consider it in the differential diagnosis of dysphagia, namely in the elderly. In fact, the disorder is probably underdiagnosed in this population group, because clinicians tend to accept other more frequent diagnosis to explain these symptoms.
- Ecodoppler Neurovascular em Contexto de UrgênciaPublication . Ferreira, S; Quintino, MF; Sá, R; Manita, M; Silva, AA; Nunes, GEm contexto de urgência o Cardiopneumologista desempenha um papel fundamental pela realização de diversos meios complementares de diagnóstico e terapêutica. Entre estes surge o Ecodoppler Neurovascular, técnica ultrassonográfica inócua, não invasiva, de fácil aplicação, que permite a obtenção de um elevado número de achados clínicos, essenciais ao encaminhamento do doente em qualquer contexto clínico. Assim este exame demonstra a sua aplicabilidade essencialmente em pacientes neurocríticos ou outros com suspeita e/ou diagnóstico de Acidente Isquémico Transitório, Acidente Vascular Cerebral (AVC), Hemorragia Subaracnoideia, Anemia das Células Falciformes e Hidrocefalia. Ainda em contexto de urgência o Ecodoppler Neurovascular assume real importância na orientação e tratamento de doentes da Via Verde AVC, uma das principais e preocupantes causas de morbilidade e mortalidade em todo o Mundo. A realização destes exames na prática hospitalar, neste conjunto de patologias, permite uma correcta e precoce orientação terapêutica, com consequente rentabilização de custos e melhorias na qualidade do tratamento. No entanto, é de referir que esta abordagem só é possível de acordo com a existência de equipas multidisciplinares de elevada relevância especialmente em contexto de urgência, local específico de encaminhamento de pacientes urgentes ou não urgentes. A título de conclusão a realização do exame Ecodoppler Neurovascular no Serviço de Urgência traduz um serviço de qualidade, permitindo redireccionar e encaminhar os doentes, adequando as devidas medidas diagnósticas e terapêuticas a instituir.
- A Estenose Intracraniana na Doença das Células FalciformesPublication . Nunes, G; Manita, M; Silva, R; Ferreira, S; Quintino, MF; Ribeiro, J; Alcântara, JO Acidente Vascular Cerebral (AVC) pode ter como origem a perturbação da circulação causada por estenose intracraniana. A Doença das Células Falciformes (DCF) é uma doença hematológica grave, mais frequente na raça negra. Caracteriza-se por alterações da configuração eritrocitária, que surge sobretudo na microcirculação, condicionando redução do lúmen arterial e vasculopatia intracraniana, sendo avaliada por Doppler Transcraniano. Avaliação da prevalência de estenose intracraniana e risco de AVC nos doentes pediátricos com DCF, seguidos em consulta de Hematologia dos Hospitais Dona Estefânia e Fernando Fonseca, durante três anos. No período compreendido entre 1 de Janeiro de 2009 e 30 de Novembro de 2011 foram avaliadas 97 crianças e adolescentes (idade <18 anos). Para o diagnóstico de estenose foi usado um Ecógrafo com sonda de 2 MHz realizando o Exame Ultrassonográfico Trancraniano Codificado a Cores (ECODTC). Para análise dos parâmetros hemodinâmicos procedeu-se de acordo com o STOP (Stroke Prevention Trial in Sickle Anemia) que estratificou intervalos hemodinâmicos para Artéria Cerebral Média, a TAMM (Time-Average Mean of Maximum Velocity), classificando-se assim o risco de AVC em “Baixo ”(< 170cm/s), “Moderado”(170 e 200cm/s) e “Elevado”(>200cm/s). Foram efectuadas reavaliações em 12, 6 a 3 meses ou 1 mês de acordo com os dados encontrados. Os 97 doentes estudados (57 sexo masculino e 40 sexo feminino) tinham idades entre os 2 e os 18 anos (média de 10,07). Ao longo dos três anos documentaram-se 6 doentes com risco Elevado, 16 com risco Moderado e os restantes 75 com Baixo risco para AVC. A prevalência de estenose intracraniana é de 22,3% (risco Moderado e risco Elevado) e de 6,2% para doentes com risco Elevado de AVC. Dos 6 doentes que apresentaram risco Elevado para AVC, 4 iniciaram Regime Transfusional Regular (RTR), 1 foi medicado com hidroxiureia e 1 fez tratamento standard. No período estudado, apenas 1 doente teve AVC, após interromper temporariamente RTR. No grupo de doentes de risco Moderado nenhum sofreu AVC e no de Baixo risco 1 encontrava-se a fazer hidroxiureia e 2 doentes sofreram AVC mas antes de realizarem periodicamente ECODTC, encontrando-se sob RTR. A avaliação por ECODTC permitiu optimizar a terapêutica transfusional e o seguimento dos doentes, tendo como principal objectivo a redução da incidência de AVC e consequentes sequelas neurológicas. Agradecimento Às Unidades de Hematologia Pediátrica do Hospital Dona Estefânia e Fernando Fonseca, pelo envio dos doentes.
- A Experiência de Um Ano na Monitorização de Estenose Intracraniana nas Crianças com Anemia de Células Falciformes (Depranocitose) por Ecodoppler TranscranianoPublication . Nunes, G; Ferreira, S; Quintino, MF; Manita, M; Ribeiro, J; Alcântara, JO Laboratório de Neurossonologia do Hospital de S. José do CHLC, EPE propôs-se avaliar os registos velocimétricos obtidos na realização de Ecodoppler Transcraniano aos doentes em idade pediátrica portadores de Drepanocitose, durante o ano de 2010, verificando-se uma baixa incidência de estenose intracraniana.
- Fabry Disease Caused by the GLA p.Phe113Leu (p.F113L) Variant: Natural History in MalesPublication . Oliveira, J; Nowak, A; Barbey, F; Torres, M; Nunes, J; Teixeira-e-Costa, F; Carvalho, F; Sampaio, S; Tavares, I; Pereira, O; Soares, A; Carmona, C; Cardoso, MT; Jurca-Simina, I; Spada, M; Ferreira, S; Germain, DBackground, aims and methods: The α-galactosidase gene (GLA) c.337T>C/p.Phe113Leu variant was originally described in patients with late-onset cardiac forms of Fabry disease (FD), who had residual α-galactosidase activity. It has since emerged as the most commonly reported GLA variant in Portuguese subjects diagnosed with FD but is also prevalent in the Italian population, where two boys carrying the GLA Leu113 allele were identified in a large-scale newborn screening program, the variant allele segregating in both cases with the same surrounding haplotype. To further delineate the genotype-phenotype correlations of this GLA variant, we have reviewed the natural history and clinical phenotypes of 11 symptomatic Portuguese males, from 10 unrelated families originating from several different areas in mainland Portugal and Madeira Island, who were diagnosed with FD associated with the GLA Leu113 allele in a diversity of clinical and screening settings. Nine of the patients were the probands of their respective families. To test whether the GLA Leu113 allele inherited by the 10 Portuguese and the two Italian families resulted from independent mutational events, we have additionally performed a haplotype analysis with 5 highly polymorphic, closely linked microsatellite markers surrounding the GLA gene. Results and conclusions: Hemizygosity for the GLA Leu113 variant allele is associated with a late-onset form of FD, invariably presenting with severe cardiac involvement. Clinically relevant cerebrovascular and kidney involvement may also occur in some patients but the pathogenic relationship between the incomplete α-galactosidase deficiency and the risks of stroke and of chronic kidney disease is not straightforward. The observation that the Leu113 allele segregated within the same GLA microsatellite haplotype in both the Portuguese and Italian families suggests its inheritance from a common ancestor.
- Height Benefit of GnRH Agonists After Age 8 in a Portuguese Cohort of Central Precocious PubertyPublication . Castro, C; Espada, F; Leite, AL; Antunes, A; Robalo, B; Amaral, D; Galo, E; Castro, S; Ferreira, S; Limbert, CObjective: Idiopathic central precocious puberty (iCPP) is common in paediatric endocrinology. Gonadotropin-releasing hormone agonists (GnRHa) are safe, but the effect on final height and the ideal timing for treatment remains controversial. This study aims to assess the effectiveness of GnRHa on growth outcomes in girls with iCPP treated before and after the age of 8 years old. Design and patients: This retrospective longitudinal study evaluated data from Portuguese girls with iCPP who completed treatment between 2010 and 2021. Measurements: Auxological and clinical characteristics were compared according to age at treatment onset. Results: A cohort of 134 girls with iCPP, was divided into early treatment (ET) (<8 years, n = 48) and later treatment (LT) groups (≥8 years, n = 86). In both groups, most children presented with Tanner II and III. Tanner IV was more frequent in LT group (p = .003). At the end of treatment, predicted adult height increased in both groups (ET p = .032; LT p = .04) and bone age significantly slowed down in all participants (p = .008, p = .034). The height gain was greater in the ET group, but without significant differences (p = .065). Conclusions: Treatment with GnRHa improved final height in all girls with iCPP, even when initiated after 8 years. To achieve better outcomes, treatment should be provided promptly after diagnosis
- Um Homem, um AVC, um Protocolo e a NeurossonologiaPublication . Nunes, G; Ferreira, S; Quintino, MF; Manita, M; Alcântara, J; Reis, J
- Impairment of Adenosinergic System in Rett syndrome: Novel Therapeutic Target to Boost BDNF SignallingPublication . Miranda-Lourenço, C; Duarte, ST; Palminha, C; Gaspar, C; Rodrigues, TM; Magalhães-Cardoso, T; Rei, N; Colino-Oliveira, M; Gomes, R; Ferreira, S; Rosa, J; Xapelli, S; Armstrong, J; García-Cazorla, A; Correia-de-Sá, P; Sebastião, AM; Diógenes, MJRett syndrome (RTT; OMIM#312750) is mainly caused by mutations in the X-linked MECP2 gene (methyl-CpG-binding protein 2 gene; OMIM*300005), which leads to impairments in the brain-derived neurotrophic factor (BDNF) signalling. The boost of BDNF mediated effects would be a significant breakthrough but it has been hampered by the difficulty to administer BDNF to the central nervous system. Adenosine, an endogenous neuromodulator, may accomplish that role since through A2AR it potentiates BDNF synaptic actions in healthy animals. We thus characterized several hallmarks of the adenosinergic and BDNF signalling in RTT and explored whether A2AR activation could boost BDNF actions. For this study, the RTT animal model, the Mecp2 knockout (Mecp2-/y) (B6.129P2 (C)-Mecp2tm1.1Bird/J) mouse was used. Whenever possible, parallel data was also obtained from post-mortem brain samples from one RTT patient. Ex vivo extracellular recordings of field excitatory post-synaptic potentials in CA1 hippocampal area were performed to evaluate synaptic transmission and long-term potentiation (LTP). RT-PCR was used to assess mRNA levels and Western Blot or radioligand binding assays were performed to evaluate protein levels. Changes in cortical and hippocampal adenosine content were assessed by liquid chromatography with diode array detection (LC/DAD). Hippocampal ex vivo experiments revealed that the facilitatory actions of BDNF upon LTP is absent in Mecp2-/y mice and that TrkB full-length (TrkB-FL) receptor levels are significantly decreased. Extracts of the hippocampus and cortex of Mecp2-/y mice revealed less adenosine amount as well as less A2AR protein levels when compared to WT littermates, which may partially explain the deficits in adenosinergic tonus in these animals. Remarkably, the lack of BDNF effect on hippocampal LTP in Mecp2-/y mice was overcome by selective activation of A2AR with CGS21680. Overall, in Mecp2-/y mice there is an impairment on adenosinergic system and BDNF signalling. These findings set the stage for adenosine-based pharmacological therapeutic strategies for RTT, highlighting A2AR as a therapeutic target in this devastating pathology.
- Papel do Enfermeiro no Posicionamento em Decúbito Ventral do Doente VentiladoPublication . Guerreiro, D; Bernardo, A; Alves, I; Ferreira, S